国际肿瘤学杂志 ›› 2018, Vol. 45 ›› Issue (5): 273-276.doi: 10.3760/cma.j.issn.1673-422X.2018.05.004

• 论著 • 上一篇    下一篇

胃泌素释放肽前体和糖类抗原72-4在胃癌患者中的表达及临床意义

李礼,孟海,赵广春,于正清,尹晓东   

  1. 224500 江苏省滨海县人民医院检验科(李礼、赵广春、于正清),消化内科(孟海),肿瘤科(尹晓东)
  • 出版日期:2018-05-08 发布日期:2018-05-23
  • 通讯作者: 尹晓东,Email: bhxylili@163.com E-mail:bhxylili@163.com

Expression and clinical significance of pro-gastrin-releasing peptide and carbohydrate antigen 72-4 in patients with gastric cancer

Li Li, Meng Hai, Zhao Guangchun, Yu Zhengqing, Yin Xiaodong   

  1. Department of Clinical Laboratory, Binhai People′s Hospital of Jiangsu Province, Binhai 224500, China
  • Online:2018-05-08 Published:2018-05-23
  • Contact: Yin Xiaodong E-mail:bhxylili@163.com

摘要: 目的探讨胃泌素释放肽前体(ProGRP)和糖类抗原724(CA724)在胃癌患者中的表达及临床应用价值。方法收集2014年1月至2016年12月,本院收治的90例胃癌患者和50例健康体检者,采用电化学发光法检测研究对象血清ProGRP和CA724水平,并分析ProGRP与胃癌临床病理特征、术后复发及CA724的关系。通过受试者工作特征(ROC)曲线分析ProGRP和CA724检测对胃癌的诊断价值。结果胃癌组患者血清ProGRP、CA724水平分别为(249.3±28.9)pg/ml、(148.8±33.5)U/ml,显著高于正常对照组的(14.4±7.6)pg/ml、(3.8±1.4)U/ml,差异均有统计学意义(t=56.320,P<0.001;t=30.504,P<0.001)。Ⅲ~Ⅳ期患者血清ProGRP水平[(269.1±30.9)pg/ml]显著高于Ⅰ~Ⅱ期患者[(198.5±23.9)pg/ml],差异有统计学意义(t=11.200,P<0.001),有淋巴结转移的患者血清ProGRP水平[(259.9±31.4)pg/ml]显著高于无淋巴结转移的患者[(190.3±26.8)pg/ml],差异有统计学意义(t=9.500,P<0.001)。术后1年复发患者血清ProGRP水平[(181.3±21.7)pg/ml]明显高于未复发患者[(26.1±12.8)pg/ml],差异有统计学意义(t=31.830,P<0.001)。胃癌患者血清ProGRP和CA724水平呈正相关(r=0.792,P=0.012)。ROC曲线显示,ProGRP取阈值为23.6 pg/ml时,其诊断胃癌的敏感性为80.0%,特异性为70.0%。CA724取阈值为11.2 U/ml时,其诊断胃癌的敏感性为60.0%,特异性为89.0%。ProGRP和CA724联合检测的敏感性和特异性分别为89.7%和94.8%,诊断价值优于单项检测(χ2=6.028,P=0.009;χ2=4.675,P=0.031)。结论胃癌患者血清中ProGRP和CA724水平显著升高且二者呈正相关,联合检测能够提高诊断敏感性和特异性。ProGRP与肿瘤分期、淋巴结转移和预后相关,可能成为胃癌预防和治疗的新靶点。

关键词: 胃肿瘤, 胃泌素释放肽前体, 糖类抗原72-4

Abstract: ObjectiveTo explore the expressions and clinical values of progastrinreleasing peptide (ProGRP) and carbohydrate antigen 724(CA724) in patients with gastric cancer. MethodsNinety patients with gastric cancer and fifty healthy subjects were selected from January 2014 to December 2016 in our hospital. Serum levels of ProGRP and CA724 were detected by electrochemiluminescence. The relationships between ProGRP and clinicopathological characteristics, postoperative recurrence and CA724 were analyzed. The diagnostic values of ProGRP and CA724 in gastric cancer were analyzed by receiver operating characteristic (ROC) curve. ResultsThe expressions of ProGRP and CA724 in patients with gastric cancer were (249.3±28.9)pg/ml and (148.8±33.5)U/ml respectively, which were significantly higher than those of healthy subjects [(14.4±7.6)pg/ml and (3.8±1.4)U/ml], and the differences were statistically sigificant (t=56.320, P<0.001; t=30.504, P<0.001). The expression of ProGRP in TNM stage ⅢⅣ [(269.1±30.9)pg/ml] was obviously higher than that in stage ⅠⅡ [(198.5±23.9)pg/ml], with a significant difference (t=11.200, P<0.001). The expression of ProGRP in patients with lymph node metastasis [(259.9±31.4)pg/ml] was significantly higher than that in patients without lymph node metastasis [(190.3±26.8)pg/ml], with a significant difference (t=9.500, P<0.001). The expression of ProGRP in patients with postoperative recurrence after one year [(181.3±21.7)pg/ml] was higer than that in patients without postoperative recurrence [(26.1±12.8)pg/ml], with a significant difference (t=31.830, P<0.001). There was a positive correlation between serum ProGRP and CA724 (r=0.792, P=0.012). According to the ROC curve, the cutoff point of ProGRP was 23.6 pg/ml, and the diagnostic sensitivity was 80.0%, the specificity was 70.0%. The cutoff point of CA724 was 11.2 U/ml, and the diagnostic sensitivity was 60.0%, the specificity was 89.0%. The sensitivity and specificity diagnostic value of combined detection were 89.7% and 94.8%, better than those of individual detection (χ2=6.028, P=0.009; χ2=4.675, P=0.031). ConclusionProGRP and CA724 are highly expressed in the serum of gastric cancer patients, with a positive correlation. The combined detection of ProGRP and CA724 can improve the diagnostic sensitivity and specificity. ProGRP is significantly correlated with tumor stage, lymph node metastasis and prognosis, which may be a mew target for prevention and treatment of gastric cancer.

Key words: Stomach neoplasms, Pro-gastrin-releasing peptide, Carbohydrate antigen 72-4